AzTrials
AzTrials

PorocarcinomaNCT03647631

Sentinel Lymph Node Biopsy in Porocarcinoma

An observational study of Porocarcinoma and Sentinel Lymph Node, run by Ospedale Policlinico San Martino at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Eccrine porocarcinoma (EPC) is a slow-growing carcinoma arising from the eccrine sweat glands. Based on its clinical presentation it can be confused with malignant and benign skin lesions, both. Histological examination is essential to formulate a correct diagnosis. Read more about this study

Who is it for?
Any age, women only
Conditions the study is for
Porocarcinoma, Sentinel Lymph Node
What is being tested?
sentinel lymph node biopsy
Type of treatment
Surgery or procedure
How many people
2 participants
Where
1 siteItaly
Study dates
17 Jul 2018to 17 Aug 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: two cases of EPC in which the sentinel lymph node biopsy (SLNB) was performed.

Who may be able to join

  • Thickness greater than or equal to 5mm
  • mitoses per 10 high-power field greater than or equal to 7
  • Immunohistochemical (IHC) analysis positive for :carcinoembryonic antigen (CEA), cytokeratin (CK) 5,7 and epithelial membrane antigen (EMA).
  • Informed consent obtained for the SNLB procedure.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Denise Palombo

    Genoa, 16036

Other trials in Italy

About this study

Official title: Sentinel Lymph Node Biopsy in Porocarcinoma: A Case Reports

Eccrine porocarcinoma (EPC) is a slow-growing carcinoma arising from the eccrine sweat glands. Based on its clinical presentation it can be confused with malignant and benign skin lesions, both. Histological examination is essential to formulate a correct diagnosis. Surgical excision with clear margins is the standard therapeutic approach while the role of sentinel lymph node biopsy (SNLB) remains controversial.

The Authors report two cases of EPC of the lower limbs occurred in two women. Patients were treated by wide surgical excision of the lesion and SNLB.

Read the detailed description

INTRODUCTION Eccrine porocarcinoma (EPC), first described by Pinkus and Mehregan in 1963, is a rare form of skin cancer. Its presentations very often mimics a cutaneous lesion similar to other forms of benign and malignant cutaneous neoplasms. Accurate diagnosis, optimal treatment and prognosis of EPC are still challenging due to scant literature reports. Eccrine carcinomas may have an elevate presence of regional lymph node metastasis, thus some authors have advocated SLNB for all or some patients, but its utility for staging purposes remains unknown.

We report two cases of EPC in which the sentinel lymph node biopsy (SLNB) was performed.

CASE PRESENTATION Case 1 During August 2017, a 64 years woman was seen at our department after a previous cutaneous lesion excision with an histological diagnosis of porocarcinoma of the left thigh. The histological examination revealed a poroid neoplasm extending into the deep dermis to the level of the dermal-subcutaneous junction with a thickness of 5.4mm, 10-12 mitoses per 10 high-power field, absence of lymphovascular invasion and free margins with a clearing distance of 1.5 mm. Hematoxilyn-eosin staining and Immunohistochemical (IHC) analysis showed positive staining for carcinoembryonic antigen (CEA), cytokeratin (CK) 5,7 and epithelial membrane antigen (EMA).

She had a past medical history of appendicitis in childhood, anxious-depressive syndrome, osteoporosis, hiatal hernia, obesity and smoked about 20 cigarettes a day. New York Heart Association (NYHA) score was 1 and American Society of Anesthesiologists (ASA) score was 1. The patient had no anorexia and weight loss and the examination did not reveal any inguinal lymphadenopathy. Laboratory tests, including blood count, biochemical investigations and serological viral markers were normal. The electrocardiogram showed sinus rhythm and the chest radiograph showed no signs of pleural or parenchymal lesions. After multidisciplinary discussion and based on the sub-optimal clearing margin we performed a re-excision of the previous wound to ensure wider safety margins of at least 20 mm similarly to surgical strategy for other skin tumors and in particular melanoma. At that time it was also decided to perform a SLNB; preoperative lymph-node scintigraphy showed the presence of two sentinel lymph nodes in the left groin that were excised during SLNB.

Case 2 During August 2017, a 65year-old female was admitted to our department with histological finding of EPC of the right leg. One month before, she underwent surgical excision of a cutaneous lesion of the right leg. This lesion appeared brownish, exophytic, with ulcerated surface, more suggestive for a squamous cell carcinoma than an ulcerated nodular basal cell carcinoma. The histological examination revealed a poroid neoplasm extending into the reticular dermis with a thickness of 5 mm, 10 mitoses per 10 high-power field, absence of lymphovascular invasion and free margins with a clearing distance of 2 mm.

She had a past medical history of hysterectomy and bilateral salpingo-oophorectomy for uterine fibromatosis, kidney transplantation for severe chronic renal failure, high blood pressure, aneurysmal dilatation of the right common carotid artery, hypercholesterolemia, hyperparathyroidism and previous inferior myocardial infarction. Laboratory tests, including blood count, biochemical investigations and serum viral markers were normal. After multidisciplinary discussion and based on the sub-optimal clearing margin we performed a re-excision of the previous wound to ensure wider safety margins of at least 20 mm. It was also decided to perform a SLNB; the pre-operative lymph node scintigraphy showed the presence of two sentinel lymph nodes in the right inguinal site. The patient underwent enlargement of the surgical excision until 20 mm of free margin from the previous excision and SLNB of the two lymph nodes identified preoperatively.

DISCUSSION EPC is a rare neoplasm arising from the intra-epidermal ductal portion of the eccrine sweat gland and represents approximately 0.005 % of all cases of malignant epithelial neoplasms.

Elderly patients are the most affected, with a peak incidence between the 6th and7th decade of life. Although it does not seem to have a predilection for sex or race, some studies indicate a slight prevalence in women. The exact etiology of EPC is unclear. Some authors suggested a possible association with radiation exposure and immunosuppression although an excessive sun exposure does not seem to be a significant risk factor. EPC may arise de novo or can develop from a pre-existing benign lesion; some clinical signs, such as spontaneous bleeding, sudden growth and ulceration in a longstanding stable lesion must lead to the suspicion of malignant degeneration. Clinically EPC can be presented as an erythematous or violaceous nodule, papule or plaque with an infiltrative or erosive pattern. EPC usually arises on the lower extremities (44%), followed by the trunk (24%), head \& neck (23%), upper extremities (11%), and rarely involves other areas. Microscopically, EPC is characterized by a cluster of anaplastic cells with nuclear hyperchromasia and important mitotic activity, extending from the epidermis to the dermis, surrounded by ductal lumen. Robinson et al. reported specific histopathologic features of EPC which may be predictive of a less favorable outcome. Thickness is the main prognostic factors for EPC. Tumors greater than 7 mm in thickness, an infiltrating front of tumor cells, the presence of lymphovascular invasion, and greater than 14 mitoses per high-power field were noted to be associated with a poorer prognosis.

The differential diagnosis includes basal and squamous cell carcinoma, adenocarcinoma, amelanotic melanoma, Bowen's disease, Paget's disease and also benign lesions like fibroma and pyogenic granuloma. Some immunohistochemical markers as carcinoembryonic antigen (CEA), EMA, and p53 protein may play a role in the diagnosis of EPC.

Therapeutic options for the treatment of EPC include electrofulguration, electrocautery, surgical excision, radiation and amputation. Surgical excision with histologically clear margins is generally considered the treatment of choice with cure rates as high as 70-80 %, although a recurrence rate of up to 20% has been reported. This elevate incidence of local recurrence may be due to a not optimal free margin at surgical excision. Lymph node metastases are present at diagnosis in 20% of cases and the incidence of visceral metastases is reported to be 10%. The tumor tends to spread tangentially in the lower third of the epidermis, then after infiltrates the dermis, subcuticular fat and lymphatic system. The role of sentinel lymph node biopsy remains controversial.

Being tested
sentinel lymph node biopsy
Medical subject headings
Eccrine Porocarcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • sentinel lymph node biopsyProcedure or surgery

    Authors discuss a possible usefulness of SNLB for staging and diagnosis in porocarcinoma.

Study groups in NCT03647631
Study groupRoleWhat they receive
Patients affected to porocarcinomaNot described
Receives: Procedure: sentinel lymph node biopsy
patients affected to porocarcinoma in our centreNot described
Receives: Procedure: sentinel lymph node biopsy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Role of SNLB in porocarcinoma in two patients evaluating the percentage of positive lymph nodes removed.

    The investigators evaluated the role of SNLB in patients affected to moderate and high risk porocarcinoma.

    Measured: Patients were treated by wide surgical excision of the lesion and SNLB. 6 months follow-up was the time frame of the study.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Aug 2018
  2. Study start17 Jul 2018
  3. Primary completion1 Aug 2018
  4. Study completion17 Aug 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Retrospective
Enrolment
2 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03647631
Sponsor's protocol ID
Chirurgia1
Status last verified
Aug 2018
First submitted
17 Aug 2018
Last updated
27 Aug 2018
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Porocarcinoma and Sentinel Lymph Node, run by Ospedale Policlinico San Martino at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Role of SNLB in porocarcinoma in two patients evaluating the percentage of positive lymph nodes removed. (time frame: Patients were treated by wide surgical excision of the lesion and SNLB. 6 months follow-up was the time frame of the study.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2018.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in